健帆生物
(300529)
| 流通市值：98.55亿 | | | 总市值：153.57亿 |
| 流通股本：5.12亿 | | | 总股本：7.99亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 560,623,604.23 | 2,011,817,980.59 | 1,556,021,993.54 | 1,134,416,582.38 |
| 营业收入 | 560,623,604.23 | 2,011,817,980.59 | 1,556,021,993.54 | 1,134,416,582.38 |
| 二、营业总成本 | 307,800,952.25 | 1,338,531,874.32 | 1,020,308,100.76 | 691,481,834.59 |
| 营业成本 | 127,540,788.3 | 428,504,854.51 | 317,573,999.79 | 228,885,193.02 |
| 税金及附加 | 11,058,515.16 | 36,789,929.28 | 27,585,735.8 | 19,818,092.43 |
| 销售费用 | 84,090,850.36 | 501,486,134.05 | 382,811,804.6 | 249,613,213.73 |
| 管理费用 | 31,325,955.98 | 131,661,596.44 | 114,569,886.31 | 75,361,306.48 |
| 研发费用 | 45,687,935.29 | 198,445,264.14 | 147,028,910.64 | 97,455,563.48 |
| 财务费用 | 8,096,907.16 | 41,644,095.9 | 30,737,763.62 | 20,348,465.45 |
| 其中:利息费用 | 12,354,915.58 | 53,511,826.05 | 40,234,062.71 | 26,824,333.3 |
| 其中:利息收入 | 5,438,922.4 | 14,471,550.8 | 10,506,736.68 | 6,987,748.97 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 9,488,846.85 | 11,065.14 | 30,921,869.97 | 21,552,025.71 |
| 加:投资收益 | 823,041.03 | 53,475,879.1 | 8,748,220.88 | 8,330,958.77 |
| 资产处置收益 | -47,499.57 | -79,851.27 | -2,843,064.1 | -1,413,498.67 |
| 资产减值损失(新) | -7,132,002.36 | -63,877,891.55 | -8,261,933.67 | -6,246,018.68 |
| 信用减值损失(新) | -1,613,136.25 | 3,379,518.23 | 3,151,415.44 | 2,485,116.42 |
| 其他收益 | 6,874,287.31 | 24,591,650.71 | 18,950,231.78 | 13,528,172.72 |
| 四、营业利润 | 261,216,188.99 | 690,786,476.63 | 586,380,633.08 | 481,171,504.06 |
| 加:营业外收入 | 4,562.73 | 15,521,805.99 | 838,449.95 | 181,148.96 |
| 减:营业外支出 | 1,206,098.49 | 46,181,185.46 | 35,165,220.08 | 19,448,664.85 |
| 五、利润总额 | 260,014,653.23 | 660,127,097.16 | 552,053,862.95 | 461,903,988.17 |
| 减:所得税费用 | 39,366,916.86 | 128,455,918.27 | 100,195,513.49 | 73,235,431.25 |
| 六、净利润 | 220,647,736.37 | 531,671,178.89 | 451,858,349.46 | 388,668,556.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 220,647,736.37 | 531,671,178.89 | 451,858,349.46 | 388,668,556.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 220,512,869.14 | 532,821,312.26 | 453,230,155.4 | 389,722,545.23 |
| 少数股东损益 | 134,867.23 | -1,150,133.37 | -1,371,805.94 | -1,053,988.31 |
| 扣除非经常损益后的净利润 | 207,916,690.53 | 512,932,081.32 | 438,090,907.89 | 372,950,435.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.28 | 0.69 | 0.59 | 0.51 |
| (二)稀释每股收益 | 0.28 | 0.69 | 0.57 | 0.49 |
| 八、其他综合收益 | - | 2,799,145.61 | - | - |
| 归属于母公司股东的其他综合收益 | - | 2,799,145.61 | - | - |
| 九、综合收益总额 | 220,647,736.37 | 534,470,324.5 | 451,858,349.46 | 388,668,556.92 |
| 归属于母公司股东的综合收益总额 | 220,512,869.14 | 535,620,457.87 | 453,230,155.4 | 389,722,545.23 |
| 归属于少数股东的综合收益总额 | 134,867.23 | -1,150,133.37 | -1,371,805.94 | -1,053,988.31 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-30 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |